Free tool
FAERS Monitor: Levoxyl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021301 or its brand name (Levoxyl, Levothyroxine Sodium). Reports on generic versions are filed under their own applications.
Reports
117,966
Serious
78,189
66% of reports
Hospitalization
42,521
Death reported
9,123
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue9,546
- nausea8,421
- diarrhoea7,430
- headache7,381
- dyspnoea7,101
- drug ineffective6,732
- pain6,113
- dizziness6,004
- asthenia5,071
- vomiting5,065
- malaise4,758
- fall4,636
- arthralgia4,591
- off label use4,474
- pruritus4,003
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,816 |
| 2005 | 2,856 |
| 2006 | 2,997 |
| 2007 | 3,561 |
| 2008 | 4,841 |
| 2009 | 4,584 |
| 2010 | 5,683 |
| 2011 | 7,244 |
| 2012 | 8,049 |
| 2013 | 2,724 |
| 2014 | 2,580 |
| 2015 | 3,359 |
| 2016 | 3,998 |
| 2017 | 4,313 |
| 2018 | 4,690 |
| 2019 | 4,493 |
| 2020 | 5,872 |
| 2021 | 6,102 |
| 2022 | 7,752 |
| 2023 | 7,252 |
| 2024 | 7,625 |
| 2025 | 8,520 |
| 2026 | 6,054 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,936,193 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fallSignal | 4,636 | 2.5 | 2.4 | 4,197 |
| astheniaSignal | 5,071 | 2.4 | 2.4 | 4,259 |
| dyspnoeaSignal | 7,101 | 2.3 | 2.2 | 5,016 |
| fatigueSignal | 9,546 | 2.2 | 2.2 | 6,414 |
| dizzinessSignal | 6,004 | 2.2 | 2.1 | 3,785 |
| headacheSignal | 7,381 | 2.1 | 2.1 | 4,401 |
| diarrhoeaSignal | 7,430 | 2.1 | 2.0 | 4,158 |
| arthralgia | 4,591 | 2.0 | 1.9 | 2,244 |
| malaise | 4,758 | 1.9 | 1.9 | 2,204 |
| vomiting | 5,065 | 1.9 | 1.9 | 2,299 |
| nausea | 8,421 | 1.9 | 1.9 | 3,732 |
| pruritus | 4,003 | 1.9 | 1.8 | 1,621 |
| pain | 6,113 | 1.8 | 1.7 | 2,139 |
| off label use | 4,474 | 0.9 | 0.9 | 41 |
| drug ineffective | 6,732 | 0.9 | 0.9 | 63 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.